Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y. Youn SW, et al. Among authors: jiang j. J Dermatolog Treat. 2022 Feb;33(1):535-541. doi: 10.1080/09546634.2020.1770174. Epub 2020 May 27. J Dermatolog Treat. 2022. PMID: 32419536 Free article. Clinical Trial.
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.
Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J, Han C, Kirby B. Errichetti E, et al. Among authors: jiang j. Acta Derm Venereol. 2024 Sep 5;104:adv41053. doi: 10.2340/actadv.v104.41053. Acta Derm Venereol. 2024. PMID: 39233617 Free PMC article. Clinical Trial.
28,090 results
You have reached the last available page of results. Please see the User Guide for more information.